Giuliani J, et al. - This examination investigated the impact of second-line therapy with anti-angiogenic agents on progression-free survival (PFS) in patients with metastatic CRC and was limited to key phase 3 randomized controlled trials (RCTs). The present analysis assessed four phase 3 RCTs, involving 3,938 subjects. For patients with metastatic CRC, aflibercept in combination with FOLFIRI is a cost-effective second-line treatment, after combining costs of drugs with the measure of efficacy denoted by the PFS.